Answers are grounded in this paper and cite their sources.
Polycystic ovarian syndrome (PCOS) is a common endocrine-metabolic disorder characterised by insulin resistance, obesity, and menstrual irregularities. Myo-inositol and metformin are frequently used for metabolic correction; however, the independent effect of myo-inositol on anthropometric outcomes remains unclear. This case report describes a 27-year-old female with PCOS who underwent sequential treatment with inositol-based regimens and metformin monotherapy. Weight reduction and improvement in body mass index were observed only during treatment phases containing inositol, whereas no anthropometric change occurred during metformin monotherapy despite equal duration. These findings suggest a potential independent contribution of myo-inositol to weight reduction. Although limited by single-patient observation, this case highlights the need for further controlled studies exploring mechanistic and clinical effects of inositol in PCOS management.
No takes yet. Share an insight, caveat, or question.
Basavaraj et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: